Abstract
Follow-up of b-amyloid (Aβ) deposition in transgenic mouse models of Alzheimer disease (AD) would be a valuable translational tool in the preclinical evaluation of potential antiamyloid therapies. This study aimed to evaluate the ability of the clinically used PET tracer 11C-Pittsburgh compound B (11C-PIB) to detect changes over time in Ab deposition in the brains of living mice representing the APP23, Tg2576, and APPswe-PS1 dE9 transgenic mouse models of AD. Methods: Mice from each transgenic strain were imaged with 60-min dynamic PET scans at 729, 12, 15, and 18222 mo of age. Regional 11C-PIB retention was quantitated as distribution volume ratios using Logan graphical analysis with cerebellar reference input, as radioactivity uptake ratios between the frontal cortex (FC) and the cerebellum (CB) during the 60-min scan, and as bound-tofree ratios in the late washout phase (40260 min). Ex vivo autoradiography experiments were performed after the final imaging session to validate 11C-PIB binding to Ab deposits. Additionally, the presence of Ab deposits was evaluated in vitro using staining with thioflavin-S and Aβ1-40, Aβ1-16, and AβN3(pE) immunohistochemistry. Results: Neocortical 11C-PIB retention was markedly increased in old APP23 mice with large thioflavin-S-positive Ab deposits. At 12 mo, the Logan distribution volume ratio for the FC was 1.03 and 0.93 (n = 2), increasing to 1.38 6 0.03 (n = 3) and 1.34 (n = 1) at 18 and 21 mo of age, respectively. An increase was also observed in bound-to-free ratios for the FC between young (7- to 12-mo-old) and old (15- to 22-mo-old) APP23 mice. Binding of 11C-PIB to Ab-rich cortical regions was also evident in ex vivo autoradiograms of APP23 brain sections. In contrast, no increases in 11C-PIB retention were observed in aging Tg2576 or APPswe-PS1dE9 mice in vivo, although in the latter, extensive Ab deposition was already observed at 9 mo of age with immunohistochemistry. Conclusion: The results suggest that 11C-PIB binding to Ab deposits in transgenic mouse brain is highly dependent on the AD model and the structure of its Ab plaques. Longitudinal in vivo 11C-PIB uptake studies are possible in APP23 mice. COPYRIGHT
| Original language | English |
|---|---|
| Pages (from-to) | 1434-1441 |
| Number of pages | 8 |
| Journal | Journal of Nuclear Medicine |
| Volume | 54 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 1 2013 |
Fingerprint
Keywords
- C-PIB
- Alzheimer disease
- Amyloid imaging
- Pittsburgh compound B
- Positron emission tomography
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Longitudinal amyloid imaging in mouse brain with 11C-PIB : Comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. / Snellman, Anniina; López-Picón, Francisco R.; Rokka, Johanna; Salmona, Mario; Forloni, Gianluigi; Scheinin, Mika; Solin, Olof; Rinne, Juha O.; Haaparanta-Solin, Merja.
In: Journal of Nuclear Medicine, Vol. 54, No. 8, 01.08.2013, p. 1434-1441.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Longitudinal amyloid imaging in mouse brain with 11C-PIB
T2 - Comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease
AU - Snellman, Anniina
AU - López-Picón, Francisco R.
AU - Rokka, Johanna
AU - Salmona, Mario
AU - Forloni, Gianluigi
AU - Scheinin, Mika
AU - Solin, Olof
AU - Rinne, Juha O.
AU - Haaparanta-Solin, Merja
PY - 2013/8/1
Y1 - 2013/8/1
N2 - Follow-up of b-amyloid (Aβ) deposition in transgenic mouse models of Alzheimer disease (AD) would be a valuable translational tool in the preclinical evaluation of potential antiamyloid therapies. This study aimed to evaluate the ability of the clinically used PET tracer 11C-Pittsburgh compound B (11C-PIB) to detect changes over time in Ab deposition in the brains of living mice representing the APP23, Tg2576, and APPswe-PS1 dE9 transgenic mouse models of AD. Methods: Mice from each transgenic strain were imaged with 60-min dynamic PET scans at 729, 12, 15, and 18222 mo of age. Regional 11C-PIB retention was quantitated as distribution volume ratios using Logan graphical analysis with cerebellar reference input, as radioactivity uptake ratios between the frontal cortex (FC) and the cerebellum (CB) during the 60-min scan, and as bound-tofree ratios in the late washout phase (40260 min). Ex vivo autoradiography experiments were performed after the final imaging session to validate 11C-PIB binding to Ab deposits. Additionally, the presence of Ab deposits was evaluated in vitro using staining with thioflavin-S and Aβ1-40, Aβ1-16, and AβN3(pE) immunohistochemistry. Results: Neocortical 11C-PIB retention was markedly increased in old APP23 mice with large thioflavin-S-positive Ab deposits. At 12 mo, the Logan distribution volume ratio for the FC was 1.03 and 0.93 (n = 2), increasing to 1.38 6 0.03 (n = 3) and 1.34 (n = 1) at 18 and 21 mo of age, respectively. An increase was also observed in bound-to-free ratios for the FC between young (7- to 12-mo-old) and old (15- to 22-mo-old) APP23 mice. Binding of 11C-PIB to Ab-rich cortical regions was also evident in ex vivo autoradiograms of APP23 brain sections. In contrast, no increases in 11C-PIB retention were observed in aging Tg2576 or APPswe-PS1dE9 mice in vivo, although in the latter, extensive Ab deposition was already observed at 9 mo of age with immunohistochemistry. Conclusion: The results suggest that 11C-PIB binding to Ab deposits in transgenic mouse brain is highly dependent on the AD model and the structure of its Ab plaques. Longitudinal in vivo 11C-PIB uptake studies are possible in APP23 mice. COPYRIGHT
AB - Follow-up of b-amyloid (Aβ) deposition in transgenic mouse models of Alzheimer disease (AD) would be a valuable translational tool in the preclinical evaluation of potential antiamyloid therapies. This study aimed to evaluate the ability of the clinically used PET tracer 11C-Pittsburgh compound B (11C-PIB) to detect changes over time in Ab deposition in the brains of living mice representing the APP23, Tg2576, and APPswe-PS1 dE9 transgenic mouse models of AD. Methods: Mice from each transgenic strain were imaged with 60-min dynamic PET scans at 729, 12, 15, and 18222 mo of age. Regional 11C-PIB retention was quantitated as distribution volume ratios using Logan graphical analysis with cerebellar reference input, as radioactivity uptake ratios between the frontal cortex (FC) and the cerebellum (CB) during the 60-min scan, and as bound-tofree ratios in the late washout phase (40260 min). Ex vivo autoradiography experiments were performed after the final imaging session to validate 11C-PIB binding to Ab deposits. Additionally, the presence of Ab deposits was evaluated in vitro using staining with thioflavin-S and Aβ1-40, Aβ1-16, and AβN3(pE) immunohistochemistry. Results: Neocortical 11C-PIB retention was markedly increased in old APP23 mice with large thioflavin-S-positive Ab deposits. At 12 mo, the Logan distribution volume ratio for the FC was 1.03 and 0.93 (n = 2), increasing to 1.38 6 0.03 (n = 3) and 1.34 (n = 1) at 18 and 21 mo of age, respectively. An increase was also observed in bound-to-free ratios for the FC between young (7- to 12-mo-old) and old (15- to 22-mo-old) APP23 mice. Binding of 11C-PIB to Ab-rich cortical regions was also evident in ex vivo autoradiograms of APP23 brain sections. In contrast, no increases in 11C-PIB retention were observed in aging Tg2576 or APPswe-PS1dE9 mice in vivo, although in the latter, extensive Ab deposition was already observed at 9 mo of age with immunohistochemistry. Conclusion: The results suggest that 11C-PIB binding to Ab deposits in transgenic mouse brain is highly dependent on the AD model and the structure of its Ab plaques. Longitudinal in vivo 11C-PIB uptake studies are possible in APP23 mice. COPYRIGHT
KW - C-PIB
KW - Alzheimer disease
KW - Amyloid imaging
KW - Pittsburgh compound B
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=84881392145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881392145&partnerID=8YFLogxK
U2 - 10.2967/jnumed.112.110163
DO - 10.2967/jnumed.112.110163
M3 - Article
C2 - 23833271
AN - SCOPUS:84881392145
VL - 54
SP - 1434
EP - 1441
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 8
ER -